# Xenon Compared to Sevoflurane and Total Intravenous Anaesthesia for Coronary Artery Bypass Graft Surgery

Study · id `cardio:ct-nct01294163` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01294163](<https://clinicaltrials.gov/study/NCT01294163>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01294163

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 509 participants.

## Technical summary

Registry record NCT01294163. Randomized; single masking; primary purpose treatment. Start 2011-04 (registry gives no type); primary completion 2014-04 (actual). Results posted on 2015-12-21.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 509 participants (enrolled count; ClinicalTrials.gov record NCT01294163, source copy `cardio:ctgov-nct01294163-2026-07-22`, retrieved 2026-10-26)
- Start date: 2011-04 (registry gives no type) (ClinicalTrials.gov record NCT01294163, source copy `cardio:ctgov-nct01294163-2026-07-22`, retrieved 2026-10-26)
- Primary completion: 2014-04 (actual) (ClinicalTrials.gov record NCT01294163, source copy `cardio:ctgov-nct01294163-2026-07-22`, retrieved 2026-10-26)
- Completion: 2014-04 (actual) (ClinicalTrials.gov record NCT01294163, source copy `cardio:ctgov-nct01294163-2026-07-22`, retrieved 2026-10-26)
- Results first posted: 2015-12-21 (ClinicalTrials.gov record NCT01294163, source copy `cardio:ctgov-nct01294163-2026-07-22`, retrieved 2026-10-26)
- Countries: France; Germany; Italy; Netherlands (ClinicalTrials.gov record NCT01294163, source copy `cardio:ctgov-nct01294163-2026-07-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01294163-2026-07-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Xenon Compared to Sevoflurane and Total Intravenous Anaesthesia for Coronary Artery Bypass Graft Surgery
- Condition: Coronary Artery Disease
- Condition: General Anesthetic Drug Allergy
- Condition: Coronary Artery Bypass Graft Surgery
- Intervention (Drug): Xenon
- Intervention (Drug): Sevoflurane
- Intervention (Drug): Propofol
- Lead sponsor: Air Liquide Santé International
- Lead sponsor class: INDUSTRY
- Collaborator: Orion Corporation, Orion Pharma
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as a collaborator: Orion Corporation, Orion Pharma (`cardio:org-orion-corporation-orion-pharma`)

## Provenance

Content hash: 6b0ef4dcf96f69b4c71db291a36c01bcfdbab29f32bad91cb59135204ea8ebea
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
